| Literature DB >> 32122895 |
Ursula Waack1,2, Edward A Weinstein3, John J Farley3.
Abstract
Animal models of bacterial infection have been widely used to explore the in vivo activity of antibacterial drugs. These data are often submitted to the U.S. Food and Drug Administration to support human use in an investigational new drug application (IND). To better understand the range and scientific use of animal models in regulatory submissions, a database was created surveying recent pneumonia models submitted as part of IND application packages. The IND studies were compared to animal models of bacterial pneumonia published in the scientific literature over the same period of time. In this review, we analyze the key experimental design elements, such as animal species, immune status, pathogens selected, and route of administration, and study endpoints.Entities:
Keywords: FDA; IND; animal models; antibiotic development
Mesh:
Substances:
Year: 2020 PMID: 32122895 PMCID: PMC7179594 DOI: 10.1128/AAC.02242-19
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191